EGFR and metastatic colorectal cancer: Erlotinib (TarcevaTM, OSI-774), a potent epidermal growth factor receptor tyrosine kinase inhibitor (EGFR), was evaluated in a phase II study to assess its activity in patients with metastatic colorectal cancer.